The FDA’s Purple Book is supposed to be the authoritative public registry for biologic drug patents in the United States. […]

How combination patent architecture protects pharmaceutical revenue after composition-of-matter expiry — and what the post-Teva v. Amneal landscape means for

When a small-molecule drug loses its composition-of-matter patent, the conventional story is that the clock runs out and generic manufacturers

Two protection systems govern pharmaceutical market exclusivity in the United States. One is a private intellectual property right, contested in

Most pharmaceutical companies treat patent disclosures as a legal obligation. The better ones treat them as a revenue forecast. The

The short answer is: yes, you can use PAT-INFORMED to find drug patent information, including grant dates and expiry dates

For most of the 20th century, pharmaceutical intellectual property was a single-act play. You discovered a molecule, filed a composition-of-matter

Every year, billions of dollars in generic-entry forecasts are built on a single assumption: that the patent expiry date listed

The moment a generic competitor files an Abbreviated New Drug Application, the brand manufacturer’s revenue clock starts ticking. But the